Vaxart (STU:NB11) YoY EBITDA Growth : 25.95% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Vaxart's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 25.95%.

Vaxart's EBITDA per Share for the three months ended in Mar. 2024 was €-0.12.

Vaxart YoY EBITDA Growth Historical Data

The historical data trend for Vaxart's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart YoY EBITDA Growth Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

69.62

49.80

-84.71

-57.96

38.58

Vaxart Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															7.06	36.36	57.34	42.31	25.95

Vaxart YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Vaxart's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.457	-	-0.744)	/	\| -0.744 \|
=	38.58 %

Vaxart's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.117	-	-0.158)	/	\| -0.158 \|
=	25.95 %

Vaxart YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Vaxart's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (STU:NB11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

VXRT:USA VXRT:Mexico

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines